(ILM1) Medios - Ratings and Ratios

Medios AG, a leading specialty pharmaceutical company based in Berlin, Germany, focuses on the distribution and manufacturing of high-quality medications tailored to specific patient needs. Since its establishment in 2016, the company has grown significantly, expanding its services and reinforcing its market position through strategic initiatives. Medios operates through two core segments: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment specializes in oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia, offering a broad range of critical medications. The Patient-Specific Therapies segment provides customized solutions, including cytostatic infusions, antibody therapies, and parenteral nutrition, catering to individual patient requirements. This segment also supports clinical trials with investigational medicinal products, underscoring Medios commitment to innovation and patient care.

As a key player in the healthcare sector, Medios AG has built a reputation for reliability and precision in the production and delivery of complex pharmaceuticals. The companys state-of-the-art facilities and adherence to stringent regulatory standards ensure the highest quality of its products. Medios AGs strategic focus on niche therapeutic areas and personalized medicine positions it as a valuable partner for healthcare providers and pharmacies across Germany. With a strong foundation in Berlin, the company continues to explore opportunities for growth and expansion in the specialty pharmaceutical market, driven by its mission to improve patient outcomes through innovative and tailored healthcare solutions.

Based on current trends, Medios AGs stock (ILM1) is expected to experience moderate volatility over the next three months. The average volume of 44,436 shares indicates consistent trading activity, while the ATR of 0.38 suggests manageable price fluctuations. The SMA 20 (12.65) and SMA 50 (12.51) are slightly above the last price of 12.26, signaling potential short-term resistance levels. The SMA 200 (14.85) remains above current prices, indicating a bearish trend in the longer term.

From a fundamental perspective, Medios AGs market cap of 339.37M EUR reflects its established presence in the specialty pharmaceutical market. The P/E ratio of 24.42 indicates a premium valuation, while the forward P/E of 8.22 suggests anticipated earnings growth. The P/B ratio of 0.64 points to undervaluation relative to book value, and the P/S ratio of 0.18 highlights the companys low revenue multiple. With an RoE of 2.54, Medios AG demonstrates moderate profitability, which is expected to improve as the company scales its operations and expands its service offerings.